OBJECTIVES: This study sought to assess the impact of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score (SXscore) on clinical outcomes in patients undergoing percutaneous coronary intervention. BACKGROUND: The SXscore has been demonstrated to have an ability to predict clinical outcomes in patients undergoing percutaneous revascularization. Current studies are limited by the relatively small number of patients in each SXscore group. METHODS: Patient-level data from 7 contemporary coronary stent trials were pooled by an independent academic research organization (Cardialysis, Rotterdam, the Netherlands). Analysis was performed on a cohort of 6,508 patients treated with drug-eluting stents and who had calculated SXscores. Clinical outcomes in terms of death, myocardial infarction (MI), repeat revascularization, and major adverse cardiac events (MACE, a composite of death, MI, and repeat revascularization) were subsequently stratified according to SXscore quartiles: SXscore(Q1) ≤ 8 (n = 1,702); 8 < SXscore(Q2) < 15 (n = 1,528); 15 ≤ SXscore(Q3) < 23 (n = 1,620); and SXscore(Q4) ≥ 23 (n = 1,658). RESULTS: One-year outcomes were available in 6,496 patients (99.8%). At 1-year follow-up, all clinical outcomes including mortality, MI, repeat revascularization, MACE, and definite and any stent thrombosis were all significantly higher in patients in the highest SXscore quartile. Similar trends were observed in a subgroup of 2,093 patients (32.2%) who presented with an ST- or non-ST-segment elevation MI. The rate of MACE among patients with an SXscore > 32 and ≤ 32 was 24.9% and 14.0%, respectively (p < 0.001). The SXscore was identified as an independent predictor of all clinical outcomes including mortality, MACE, and stent thrombosis (p < 0.001 for all). CONCLUSIONS: This study confirms the consistent ability of the SXscore to identify patients who are at highest risk of adverse events.
OBJECTIVES: This study sought to assess the impact of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score (SXscore) on clinical outcomes in patients undergoing percutaneous coronary intervention. BACKGROUND: The SXscore has been demonstrated to have an ability to predict clinical outcomes in patients undergoing percutaneous revascularization. Current studies are limited by the relatively small number of patients in each SXscore group. METHODS:Patient-level data from 7 contemporary coronary stent trials were pooled by an independent academic research organization (Cardialysis, Rotterdam, the Netherlands). Analysis was performed on a cohort of 6,508 patients treated with drug-eluting stents and who had calculated SXscores. Clinical outcomes in terms of death, myocardial infarction (MI), repeat revascularization, and major adverse cardiac events (MACE, a composite of death, MI, and repeat revascularization) were subsequently stratified according to SXscore quartiles: SXscore(Q1) ≤ 8 (n = 1,702); 8 < SXscore(Q2) < 15 (n = 1,528); 15 ≤ SXscore(Q3) < 23 (n = 1,620); and SXscore(Q4) ≥ 23 (n = 1,658). RESULTS: One-year outcomes were available in 6,496 patients (99.8%). At 1-year follow-up, all clinical outcomes including mortality, MI, repeat revascularization, MACE, and definite and any stent thrombosis were all significantly higher in patients in the highest SXscore quartile. Similar trends were observed in a subgroup of 2,093 patients (32.2%) who presented with an ST- or non-ST-segment elevation MI. The rate of MACE among patients with an SXscore > 32 and ≤ 32 was 24.9% and 14.0%, respectively (p < 0.001). The SXscore was identified as an independent predictor of all clinical outcomes including mortality, MACE, and stent thrombosis (p < 0.001 for all). CONCLUSIONS: This study confirms the consistent ability of the SXscore to identify patients who are at highest risk of adverse events.
Authors: Philippe Généreux; Tullio Palmerini; Adriano Caixeta; Gregg Rosner; Philip Green; Ovidiu Dressler; Ke Xu; Helen Parise; Roxana Mehran; Patrick W Serruys; Gregg W Stone Journal: J Am Coll Cardiol Date: 2012-04-04 Impact factor: 24.094
Authors: Jason C Kovacic; Atul M Limaye; Samantha Sartori; Paul Lee; Roshan Patel; Sweta Chandela; Biana Trost; Swathi Roy; Rafael Harari; Birju Narechania; Rucha Karajgikar; Michael C Kim; Prakash Krishnan; Pedro Moreno; Usman Baber; Roxana Mehran; George Dangas; Annapoorna S Kini; Samin K Sharma Journal: Catheter Cardiovasc Interv Date: 2013-07-01 Impact factor: 2.692
Authors: Christoph Sinning; Lars Lillpopp; Sebastian Appelbaum; Francisco Ojeda; Tanja Zeller; Renate Schnabel; Edith Lubos; Annika Jagodzinski; Till Keller; Thomas Munzel; Christoph Bickel; Stefan Blankenberg Journal: Clin Res Cardiol Date: 2013-03-23 Impact factor: 5.460
Authors: Issam D Moussa; Lloyd W Klein; Binita Shah; Roxana Mehran; Michael J Mack; Emmanouil S Brilakis; John P Reilly; Gilbert Zoghbi; Elizabeth Holper; Gregg W Stone Journal: J Am Coll Cardiol Date: 2013-10-22 Impact factor: 24.094
Authors: Felipe C Fuchs; Jorge P Ribeiro; Flávio D Fuchs; Marco V Wainstein; Luis C Bergoli; Rodrigo V Wainstein; Vanessa Zen; Alessandra C Kerkhoff; Leila B Moreira; Sandra C Fuchs Journal: Arq Bras Cardiol Date: 2016-08-08 Impact factor: 2.000